<div id="readability-page-1"><p>Oscar Health, Inc. (NYSE:OSCR - Get Free Report) dropped 7.9% during mid-day trading on Thursday after Barclays lowered their price target on the stock from $17.00 to $11.00. Barclays currently has an underweight rating on the stock. Oscar Health traded as low as $14.65 and last traded at $14.62. Approximately 20,708,746 shares changed hands during trading, an increase of 67% from the average daily volume of 12,433,063 shares. The stock had previously closed at $15.87.</p><ul><li>5 Small Cap Stocks With Explosive Upside Potential</li></ul><p>A number of other research analysts also recently commented on OSCR. Wells Fargo &amp; Company downgraded Oscar Health from an &#34;equal weight&#34; rating to an &#34;underweight&#34; rating and dropped their price target for the company from $16.00 to $10.00 in a research note on Friday, July 11th. Piper Sandler downgraded Oscar Health from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and set a $14.00 price target for the company. in a research note on Monday, July 14th. Wall Street Zen downgraded Oscar Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, June 8th. UBS Group  restated a &#34;sell&#34; rating and issued a $11.00 target price (down previously from $15.00) on shares of Oscar Health in a research report on Tuesday, July 15th. Finally, Raymond James Financial lowered shares of Oscar Health from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Tuesday, June 24th. Five research analysts have rated the stock with a sell rating and three have issued  a hold rating to the company's stock. Based on data from MarketBeat, Oscar Health presently has a consensus rating of &#34;Reduce&#34; and an average price target of $11.92.</p><p><b>Read Our Latest Stock Report on Oscar Health</b></p><h2>Insider Buying and Selling</h2><p>In related news, Director Elbert O. Jr. Robinson sold 25,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $16.43, for a total value of $410,750.00. Following the sale, the director directly owned 64,512 shares in the company, valued at $1,059,932.16. This represents a 27.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 24.39% of the stock is owned by insiders. </p><h2>Hedge Funds Weigh In On Oscar Health</h2><p>A number of institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC raised its position in shares of  Oscar Health by 2.7% during the first quarter. Hsbc Holdings PLC now owns 24,113 shares of the company's stock worth $313,000 after purchasing an additional 632 shares during the period.  Tempus Wealth Planning LLC raised its position in  Oscar Health by 6.7% in the 1st quarter. Tempus Wealth Planning LLC now owns 14,392 shares of the company's stock valued at $189,000 after buying an additional 906 shares during the last quarter.  Focus Partners Wealth raised its position in  Oscar Health by 1.8% in the 1st quarter. Focus Partners Wealth now owns 55,158 shares of the company's stock valued at $723,000 after buying an additional 949 shares during the last quarter.  Xponance Inc. raised its position in  Oscar Health by 7.1% in the 1st quarter. Xponance Inc. now owns 15,423 shares of the company's stock valued at $202,000 after buying an additional 1,029 shares during the last quarter.  Finally, CWM LLC raised its position in  Oscar Health by 50.7% in the 1st quarter. CWM LLC now owns 3,204 shares of the company's stock valued at $42,000 after buying an additional 1,078 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors. </p><h2>Oscar Health Price Performance</h2><p>The firm has a market capitalization of $3.73 billion, a PE ratio of 52.20 and a beta of 1.90. The business has a 50-day moving average of $16.10 and a 200 day moving average of $14.92. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 0.22. </p><p>Oscar Health (NYSE:OSCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.09. Oscar Health had a return on equity of 10.59% and a net margin of 1.22%. The firm had revenue of $3 billion during the quarter, compared to analyst estimates of $2.87 billion. During the same period last year, the firm posted $0.62 EPS. The business's revenue was up 42.2% compared to the same quarter last year.  As a group, research analysts anticipate that  Oscar Health, Inc. will post 0.69 EPS for the current fiscal year. </p><h2>About Oscar Health</h2> (Get Free Report)<p>Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Oscar Health</li><li>3 Tickers Leading a Meme Stock Revival</li><li>Why Options Traders Are Betting Big on Oracle Stock </li><li>Consumer Discretionary Stocks Explained</li><li>Alphabet’s Breakout Quarter Signals a New Leadership Phase</li><li>Do ETFs Pay Dividends? What You Need to Know</li><li>Rivian Stock Rallies as Robotaxi Buzz Builds</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Oscar Health Right Now?</h2><p>Before you consider Oscar Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.</p><p>While Oscar Health currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OSCR

<p>Oscar Health (NYSE:OSCR) shares fell 7.9% after Barclays downgraded its price target from $17.00 to $11.00, maintaining an underweight rating. The stock traded as low as $14.65, with a significant increase in trading volume. Other analysts, including Wells Fargo and Piper Sandler, also downgraded the stock, contributing to a consensus rating of "Reduce" and an average price target of $11.92. Insider trading activity showed a director sold 25,000 shares, reducing ownership by 27.93%. Oscar Health reported a revenue increase of 42.2% year-over-year in its latest earnings report.</p>

Oscar Health (NYSE:OSCR) Stock Price Down 7.9% After Analyst Downgrade